[A clinical case of pulmonary thromboembolism in a patient at risk treated with rt-pA].
After a brief mention of new advances in the pathophysiology of fibrinolysis, the authors outline the pharmacological properties of the new thrombolytic agent rt-pA versus classic thrombolytic agent urokinase and streptokinase. Thereafter they report a case of acute pulmonary embolism with severe hypoxemia in a patient with a history of recent traumatic cerebral bleeding. Thrombolytic treatment with rt-pA (100 mg/2 h) resulted in a satisfactory clinical outcome without appreciable worsening of intracranial injury.
Giuliano
A L
AL
Damato
A
A
Pagano
A
A
Merla
M
M
Langiano
E
E
Valeri
F
F
D000328:Adult; D001930:Brain Injuries / Q000150:complications; D006801:Humans; D008297:Male; D010958:Plasminogen / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012307:Risk Factors
D011994:Recombinant Proteins; D010958:Plasminogen
Su di un caso clinico di TEP in un paziente a rischio trattato con rt-pA.